Enovis Corporation (ENOV)

NYSE • Healthcare

$21.08

-$0.51 (-2.4%)

Market open

Last close at October 23, 2026 at 20:00 UTC

Open$21.39

Previous Close$21.08

Day Range$20.86 - $21.7

Avg. Volume (3M)1.3M

Market Cap$1.2B

52 Week Range

$16.7$34.28

Next EarningsIn 11 daysNov 5, 2026

Metrics Over Time

Where the Money Goes

Q3 2026

Revenueeverything earned$582.7M100%

Gross Profitminus cost of goods$359.2M62%

Operating Incomeminus R&D and overhead$17.4M3%

Fundamentals & Financials

Revenue (TTM)

$2.2B

Net Income (TTM)

-$1.1B

EPS (TTM)

-$19.4

ROA (TTM)

-29.25%

Current Ratio

1.98

Dividend Yield

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Income Statement

Balance Sheet

Financial Highlights

Dividends History

Split History

Earnings

+6.8%Q3 2025$0.79

+11.9%Q4 2025$0.75

+17.3%Q1 2026$0.95

+8.5%Q2 2026$0.89

+6.3%Q3 2026$0.9

Nov 5

in 11 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026

Beat +6.3%

Enovis Corporation beat consensus on both the top and bottom line in the second fiscal quarter of 2026, reported August 6 based on preliminary results, as adjusted EPS of $0.90 topped the $0.85 estimate by 6.3% and revenue of about $582.8 million edged the $581.8 million consensus by 0.2%. Revenue rose about 3% from about $564.5 million a year ago, while gross margin held near 62% and operating margin was about 3% as operating income came in around $17.4 million. Adjusted EPS was up about 14% from $0.79 a year ago, and the company generated operating cash flow of $75.0 million. Consensus for the next period calls for adjusted EPS of $0.85 on revenue of $562.1 million.

Next report — what to expect

Enovis Corporation (ENOV) reports on November 5, 2026. Wall Street is looking for consensus EPS of $0.76 on revenue of $557.1 million. For trailing context, revenue rose +3.2% year over year last quarter. ENOV has beaten EPS in 8 of its 8 most recent quarters.

View full earnings history

About Enovis Corporation

Enovis Corporation is a medical device company listed on the NYSE as ENOV that develops and sells orthopedic, rehabilitation, and reconstructive products worldwide. Under the DJO brand, it generated $2.2 billion of revenue in FY2025 from a portfolio that spans bracing, therapy, and implantable joint-reconstruction products.

Name

Enovis Corporation

CEO

Damien McDonald

Website

www.enovis.com

Industry

Healthcare

Employees

7,802

Today's Snapshot

AI-generated

ENOV closed 2.4% below yesterday's close, in line with a weaker sector. ENOV reports earnings on 5 November.

Trading Volume

Below 10d avg (1.2M)

952.8K

vs S&P 500 Today

Underperforming Market

-1.84%

Updated: October 23, 2026 at 20:21 UTC

Technical Indicators

4 Buy1 Neutral3 Sell

ENOV exhibits constructive short-term strength as price sits above the 10–50 period moving averages while remaining below the 100–200 day levels, indicating near-term upside facing longer-term resistance. Momentum is positive—CCI and MACD are bullish and RSI is in the upper-neutral range—while ADX near 23 signals a modest trend. Volatility is moderate and the stock trades near the upper Bollinger band, with pivot levels roughly aligned to the market. OBV shows buying interest despite a negative cumulative figure. Technical takeaway: Buy — short-term momentum supportive but longer-term averages present resistance.

All signals